LY4268989

LY4268989 (zotemtegrast, originally MORF-057) is an oral α4β7 integrin inhibitor that Eli Lilly inherited when it bought Morphic Holding for $3.2 billion in 2024 [6]. It is the most advanced attempt to put Takeda's $6-billion-a-year Entyvio franchise into a pill, currently in two parallel Phase 2 trials in moderately-to-severely active ulcerative colitis (UC) - one as monotherapy [2], one in combination with Lilly's own approved IL-23 antibody mirikizumab [1]. The key near-term catalyst is the EMERALD-2 Phase 2b readout, which Lilly disclosed at its Q1 2026 earnings call is expected in August 2026 [12]. Lilly has already initiated EMERALD-3 Phase 3 in February 2026, signaling internal confidence in the program ahead of EMERALD-2 topline [13].

This is a novel compound, Lilly's first oral α4β7, acquired through Morphic in 2024 [6]. No FDA designations have been disclosed. Phase 1 in healthy volunteers (NCT06964776, n=144) is complete [5]; specific PK and hepatic safety data have not been publicly disclosed beyond a general well-tolerated label. Two Phase 2 trials are recruiting: NCT07415044 is a monotherapy study with a 1,431-patient enrollment target [2], and NCT07186101 randomizes 252 patients to LY4268989 plus mirikizumab versus mirikizumab alone [1]. The Phase 2b EMERALD-2 (NCT05611671) randomized 282 patients across three active doses (100 mg BID, 200 mg BID, and a once-daily arm) plus placebo under Morphic and is active-not-recruiting; Lilly disclosed at the Q1 2026 earnings call that EMERALD-2 topline is expected in August 2026 [12]. Phase 2a EMERALD-1 (NCT05291689) main cohort (n=35 evaluable) met its primary endpoint in 2023 with 25.7% mMCS clinical remission, 45.7% clinical response, and 25.7% endoscopic improvement at week 12; the published 52-week analysis reported 22.9% RHI histologic remission (Clinical Gastroenterology and Hepatology, February 2026) [3][14]. The 1,431-patient monotherapy Phase 2 is unusually large - Lilly is effectively running a registrational-scale study under a Phase 2 label, which compresses timeline if Phase 3 is greenlit. EMERALD-3 (Phase 3) was first registered February 2026 with ~108-week per-participant duration, indicating Lilly began Phase 3 logistics before EMERALD-2 readout [13]. Lilly is also developing zotemtegrast monotherapy in Crohn's disease per its Q1 2026 pipeline update, mirroring vedolizumab's dual-indication strategy [12]. No PDUFA date exists yet.

The α4β7 integrin is a homing receptor on inflammatory T cells. It binds MAdCAM-1, a protein expressed almost exclusively on blood vessels in the gut, so when you block α4β7, you stop inflammatory immune cells from getting into the gut wall without crippling immune surveillance elsewhere. That gut-selective angle matters. Natalizumab (Tysabri) hits α4β1 to α4β7, and α4β1 patrols the brain - that drug has been linked to a rare and sometimes fatal brain infection called PML (progressive multifocal leukoencephalopathy) [8]. α4β7 alone is the cleaner target. The mechanism is genetically and pharmacologically validated. Takeda's vedolizumab (Entyvio), an injected antibody against α4β7, has been on the market since 2014 for UC and Crohn's and pulled in roughly $6 billion in FY2024 [7][9]. Induction clinical remission rates run around 17-19% versus 5-8% on placebo [7]. The scientific question with zotemtegrast is not target validity - vedolizumab settled that - but whether a small molecule taken orally can hit the target with antibody-like potency and gut selectivity. Morphic's EMERALD-1 Phase 2a data (25.7% clinical remission, 25.7% endoscopic improvement at week 12 in an open-label n=35 cohort) suggested yes, with response rates broadly consistent with vedolizumab in a small population [3][14]. The combination trial with mirikizumab tests a different question. Mirikizumab blocks IL-23, a cytokine that drives gut inflammation from a different angle than trafficking. Hitting the gut from two angles - block the cells getting in, then block the signaling once they arrive - could yield additive efficacy, or pile on infection risk without proportionate benefit.

Two parallel Phase 2 trials. NCT07415044 randomizes 1,431 patients with moderately-to-severely active UC to LY4268989 or placebo for 12 weeks of induction, then maintenance, with the primary endpoint of clinical remission by modified Mayo Score (mMS) at week 12 [2]. The modified Mayo Score rates UC severity on a 0-9 scale combining stool frequency, rectal bleeding, and endoscopy findings; remission requires all subscores at or near zero (including a centrally-read endoscopy subscore ≤1), which is a stricter bar than symptom relief alone because it demands confirmed mucosal healing on colonoscopy. This enrollment size is unusually large for Phase 2 - most Phase 2 UC studies sit at 200-400 patients. Lilly is running registrational-scale numbers under a Phase 2 label, which suggests confidence in the mechanism and a desire to compress development time if signals hold. NCT07186101 randomizes 252 patients to LY4268989 plus mirikizumab versus mirikizumab alone, same primary endpoint [1]. This is the harder design: beating an active comparator that already produces around 25% remission at week 12 means LY4268989 has to add meaningful incremental efficacy to register a signal. It is also the more interesting question scientifically - does dual-mechanism inhibition (trafficking plus IL-23 signaling) actually compound? Both trials enroll moderately-to-severely active UC defined by mMS 4-9 with endoscopy subscore at least 2, with a mix of biologic-naive and biologic-experienced patients. No biomarker enrichment, which fits the mechanism: α4β7 expression is broad on gut-trafficking lymphocytes and has not stratified responders in vedolizumab studies [7]. The earlier EMERALD-2 Phase 2b (NCT05611671) randomized 282 patients across three active dose regimens (100 mg BID, 200 mg BID, and a once-daily arm) plus placebo; its readout is the most consequential near-term data point because it tests the dose and induction-maintenance schema Lilly will carry into Phase 3 [4][12].

Our model puts the chance of this drug eventually getting approved at 17%. That starts from the historical approval rate for Phase 2 drugs in this area, which is about 30%, then adjusts based on ten specific facts about the trial and its sponsor. The estimate is helped by larger-than-typical enrollment, more secondary endpoints than usual, and the sponsor's strong approval track record - but pulled down by weak earlier-phase results. The remaining factors are close to average for this stage, so they don't shift the number much either way.

Efficacy is the dominant risk. Vedolizumab's induction remission rates run 17-19% - real efficacy, but not transformative [7]. If zotemtegrast lands at 12-15%, the drug works but does not clearly displace Entyvio's maintenance profile or beat JAK inhibitors (upadacitinib/Rinvoq, tofacitinib/Xeljanz) and IL-23 antibodies (mirikizumab, risankizumab/guselkumab) on convenience alone. The combination trial inherits this ceiling: if mirikizumab monotherapy already hits ~25% remission, the combination has to add roughly 10 percentage points to justify dual-mechanism cost and infection exposure [1]. Safety has two flags. First, oral bioavailability changes systemic exposure. Small molecules typically distribute more broadly than antibodies, so the gut selectivity that protects antibody α4β7 inhibitors from systemic immunosuppression is not automatic for a pill. Phase 1 in healthy volunteers (NCT06964776) is complete but specific PK ranges, exposure-response data, and any hepatic enzyme signals have not been publicly disclosed [5]. Second, etrolizumab's Phase 3 failures (HIBISCUS, GARDENIA, LAUREL, HICKORY) showed that adjacent integrin biology can produce noisy late-stage results even when Phase 2 looked clean [11]. The mechanism did not change between trials; patient heterogeneity and endpoint stringency did. Execution risk centers on enrollment pace. The 1,431-patient monotherapy trial is large and the UC trial space is competitive; recruiting against ongoing trials of guselkumab, risankizumab, and several S1P modulators means slot competition is real [2]. Commercial risk persists even with positive data. The UC market is crowded with vedolizumab, JAKs, IL-23s, anti-TNFs, and S1P modulators (ozanimod/Zeposia). Payers will demand head-to-head superiority or a clear convenience advantage to grant formulary parity. Oral dosing helps, but mirikizumab and risankizumab already have strong induction-maintenance profiles. Vedolizumab biosimilar entry is a second-order pricing risk: Polpharma Biologics and Alvotech have vedolizumab biosimilar programs in Phase 3 with expected launches in the 2028-2032 window [15]. When biosimilar Entyvio enters at a steep discount, the reference price for the α4β7 mechanism compresses, and an oral α4β7 needs to either compete on price or demonstrate clear clinical superiority to justify a premium - a tougher bar than the writeup would have framed two years ago.

Worth watching, with a hard catalyst date. The $3.2 billion Morphic acquisition price set a bar Lilly has to clear: Phase 2b has to read out cleanly to justify the spend, which is why you are seeing the unusually large 1,431-patient monotherapy trial and the early February 2026 launch of EMERALD-3 logistics - Lilly is running for the registrational lane and pre-committing capital ahead of EMERALD-2 topline [2][6][13]. The signal to watch is the EMERALD-2 readout (NCT05611671), which Lilly disclosed will land in August 2026 [12]: clinical remission separation from placebo at week 12, plus endoscopic improvement rate. Anything in the 17-20% remission band puts zotemtegrast in vedolizumab territory and makes Phase 3 a green light. Below 13% and the strategic logic of the acquisition becomes hard to defend. The mirikizumab combination trial [1] is the more interesting science but the lower-probability commercial play; the monotherapy trial determines whether Lilly built a new IBD franchise or paid $3.2 billion for a science project. Two structural caveats worth pricing in: (1) vedolizumab biosimilars from Polpharma and Alvotech are in Phase 3 with 2028-2032 launch windows [15] - if Entyvio loses pricing power before zotemtegrast launches, the premium an oral α4β7 can command shrinks, and the program needs clinical superiority (not just convenience) to justify reimbursement; and (2) Lilly disclosed at Q1 2026 earnings that zotemtegrast monotherapy is also being developed in Crohn's disease, mirroring vedolizumab's dual-indication strategy [12] - Crohn's adds meaningful TAM if the mechanism translates, but the EMERALD trials are all UC, so CD risk sits entirely in front of us. Check back when EMERALD-2 reads out in August 2026.